{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T04:22:09Z","timestamp":1774153329626,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.04.015","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T19:51:53Z","timestamp":1712605913000},"page":"3091-3098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-2658","authenticated-orcid":false,"given":"Min","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9295-4252","authenticated-orcid":false,"given":"Ming-Zhu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiguo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangzhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan-Shan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuqiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2804-0827","authenticated-orcid":false,"given":"Qing-Bin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vaccine.2024.04.015_b0005","doi-asserted-by":"crossref","first-page":"e0133620","DOI":"10.1371\/journal.pone.0133620","article-title":"Pneumonia mortality among children under 5 in China from 1996 to 2013: an analysis from national surveillance system","volume":"10","author":"He","year":"2015","journal-title":"PLoS One"},{"issue":"33","key":"10.1016\/j.vaccine.2024.04.015_b0010","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1016\/j.vaccine.2021.06.075","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study","volume":"39","author":"Zhang","year":"2021","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.04.015_b0015","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"5","key":"10.1016\/j.vaccine.2024.04.015_b0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.vaccine.2024.04.015_b0025","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1183\/13993003.01451-2015","article-title":"Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm","volume":"47","author":"Galanis","year":"2016","journal-title":"Sweden Eur Respir J"},{"key":"10.1016\/j.vaccine.2024.04.015_b0030","article-title":"Direct and indirect effects of 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in children hospitalised with pneumonia from formal and informal settlements in Mongolia: an observational study","volume":"15","author":"Chan","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.vaccine.2024.04.015_b0035","doi-asserted-by":"crossref","unstructured":"Guevara M, Barricarte A, Torroba L, et al. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study. Euro Surveill 2016; 21(14).","DOI":"10.2807\/1560-7917.ES.2016.21.14.30186"},{"issue":"32","key":"10.1016\/j.vaccine.2024.04.015_b0040","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1016\/j.vaccine.2019.06.071","article-title":"Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006\u20132018","volume":"37","author":"Andrews","year":"2019","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2024.04.015_b0045","first-page":"1435","article-title":"Effectiveness of 13-valent pneumococcal polysaccharide conjugate vaccine on community-acquired pneumonia: a retrospective cohort study among young children in Suzhou city","volume":"38","author":"Zhao-jin","year":"2022","journal-title":"Chin. J. Public Health"},{"key":"10.1016\/j.vaccine.2024.04.015_b0050","unstructured":"on CPMATFotMoR-WS, Effectiveness IV. Expert consensus on methodology for real-world studies of influenza vaccine effectiveness. Chinese Journal of Vaccines and Immunization 2022; 06(28): 617-37."},{"issue":"43","key":"10.1016\/j.vaccine.2024.04.015_b0055","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1016\/j.vaccine.2017.09.005","article-title":"The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: a systematic review and meta-analysis","volume":"35","author":"Alicino","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.04.015_b0060","unstructured":"Lin L-z. Evaluation of the cost-effectiveness and effects of 13-valent pneumococcal conjugate vaccine for children under 2 years old in Ningbo City: Ningbo University; 2020."},{"key":"10.1016\/j.vaccine.2024.04.015_b0065","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1017\/S0950268820000813","article-title":"Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan","volume":"148","author":"Takeuchi","year":"2020","journal-title":"Epidemiol. Infect."},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.015_b0070","doi-asserted-by":"crossref","first-page":"e0168209","DOI":"10.1371\/journal.pone.0168209","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on clinical and hypoxemic childhood pneumonia over three years in central malawi: an observational study","volume":"12","author":"McCollum","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2024.04.015_b0075","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1093\/cid\/ciaa919","article-title":"Effect of haemophilus influenzae Type b and 13-valent pneumococcal conjugate vaccines on childhood pneumonia hospitalizations and deaths in botswana","volume":"73","author":"Congdon","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2024.04.015_b0080","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1093\/cid\/ciz462","article-title":"Pneumococcal conjugate vaccine impact on meningitis and pneumonia among children aged <5 years-Zimbabwe, 2010\u20132016","volume":"69","author":"Dondo","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.vaccine.2024.04.015_b0085","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10096-021-04386-0","article-title":"The impact of pneumococcal conjugate vaccine on the prevalence and severity of hospitalizations for pneumonia in children","volume":"41","author":"Eichler","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"8","key":"10.1016\/j.vaccine.2024.04.015_b0090","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1093\/cid\/ciz1164","article-title":"Dose-specific effectiveness of 7- and 13-valent pneumococcal conjugate vaccines against vaccine-serotype streptococcus pneumoniae colonization in children","volume":"71","author":"Lewnard","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"52","key":"10.1016\/j.vaccine.2024.04.015_b0095","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1016\/j.vaccine.2020.11.004","article-title":"Incidence of community-acquired pneumonia in urban China: a national population-based study","volume":"38","author":"Sun","year":"2020","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2024.04.015_b0100","doi-asserted-by":"crossref","first-page":"e0171438","DOI":"10.1371\/journal.pone.0171438","article-title":"High pneumonia lifetime-ever incidence in Beijing children compared with locations in other countries, and implications for national PCV and Hib vaccination","volume":"12","author":"Qu","year":"2017","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.vaccine.2024.04.015_b0105","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1080\/21645515.2017.1304335","article-title":"Disease burden of community acquired pneumonia among children under 5 y old in China: a population based survey","volume":"13","author":"Li","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"7","key":"10.1016\/j.vaccine.2024.04.015_b0110","first-page":"28","article-title":"The analysis of the effect of clinical pathway nursing on hospitalized children with mycoplasma pneumonia","volume":"13","author":"Yang","year":"2015","journal-title":"Contemporary Medical Symposium"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.015_b0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1524-4733.2008.00410.x","article-title":"Potential for cost-savings in the care of hospitalized low-risk community-acquired pneumonia patients in China","volume":"12","author":"Zhou","year":"2009","journal-title":"Value Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24004298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24004298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T05:55:26Z","timestamp":1725688526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24004298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24004298"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}